Your prediction
Cerenis Therapeutics Holding S.A. Stock
We can see a decrease in the price for Cerenis Therapeutics Holding S.A.. Compared to yesterday it has lost -€0.060 (-1.570%).
Our community identified positive and negative aspects for Cerenis Therapeutics Holding S.A. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Cerenis Therapeutics Holding S.A. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cerenis Therapeutics Holding S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cerenis Therapeutics Holding S.A. | -1.570% | -7.457% | -2.323% | - | - | - | - |
| Genoway S.A. Inh. | -1.580% | 1.220% | -4.231% | -32.703% | -31.215% | -38.060% | -15.878% |
| Sensorion SA | -5.460% | -6.734% | -13.438% | -58.283% | -53.679% | -24.626% | -81.284% |
| Hybrigenics S.A. | 3.850% | -3.571% | -6.897% | -26.027% | -15.625% | -91.818% | -97.340% |
News
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
Regulatory News:
ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, today announced the publication of a ground breaking